Evidence map›Paper›PMID 37074930›Full record

ArticleNeuro-oncology2023

Stem-like signatures in human meningioma cells are under the control of CXCL11/CXCL12 chemokine activity.

Federica Barbieri, Adriana Bajetto, Irene Dellacasagrande, Agnese Solari, Roberto Würth, Virginia Fernandez, Silvia Rancati, Davide Ceresa, Irene Appolloni, Giuseppa De Luca and 13 more

Open access · greenAbstract read
In one paragraph

Article in Neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Cancer stem cells in meningiomas: novel insights and therapeutic implications.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  7. Article
  8. Article
  9. International journal of molecular sciences · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Federica BarbieriSection of Pharmacology, Department of Internal Medicine, University of Genova, Genova, Italy.
Adriana BajettoSection of Pharmacology, Department of Internal Medicine, University of Genova, Genova, Italy.
Irene DellacasagrandeSection of Pharmacology, Department of Internal Medicine, University of Genova, Genova, Italy.
Agnese SolariSection of Pharmacology, Department of Internal Medicine, University of Genova, Genova, Italy.
Roberto WürthSection of Pharmacology, Department of Internal Medicine, University of Genova, Genova, Italy.
Virginia FernandezNeurobiology of miRNA, Istituto Italiano di Tecnologia (IIT), Genova, Italy.
Silvia RancatiNeurobiology of miRNA, Istituto Italiano di Tecnologia (IIT), Genova, Italy.
Davide CeresaIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Irene AppolloniDepartment of Experimental Medicine, University of Genova, Genova, Italy.
Giuseppa De LucaIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Mariella DonoIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Paolo NozzaIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Piero SchiapparelliMedical Physics Department, E.O. Galliera Hospital, Genova, Italy.
Monica GambaroMedical Physics Department, E.O. Galliera Hospital, Genova, Italy.
Pietro FiaschiIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Gabriele GaggeroIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Nicolò CostanzoSection of Pharmacology, Department of Internal Medicine, University of Genova, Genova, Italy.
Stefano ThellungSection of Pharmacology, Department of Internal Medicine, University of Genova, Genova, Italy.
Paolo MalatestaIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Aldo PaganoIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Gianluigi ZonaIRCCS Ospedale Policlinico San Martino, Genova, Italy.
Davide De Pietri TonelliNeurobiology of miRNA, Istituto Italiano di Tecnologia (IIT), Genova, Italy.
Tullio FlorioSection of Pharmacology, Department of Internal Medicine, University of Genova, Genova, Italy.ORCID 0000-0002-2394-996X
Ospedale Policlinico San Martino · ITUniversity of Genoa · ITItalian Institute of Technology · ITEnte Ospedaliero Ospedali Galliera · IT

Funding

AIRC-IG 20106
6 · The paper itself

Abstract

backgroundMeningiomas are mainly benign brain tumors, although about 20% of histologically benign cases are clinically aggressive and recur after resection. We hypothesize that meningioma brain invasiveness and recurrence may be related to the presence of cancer stem cells and their high responsiveness to the CXCL12-CXCR4/CXCR7 chemokine axis. The aim of this study was to isolate meningioma stem cells from human samples, characterize them for biological features related to malignant behavior, and to identify the role of CXCR4/CXCR7 in these processes.

methodsMeningioma stem cells were isolated from patient-derived primary cultures in stem cell-permissive conditions, and characterized for phenotype, self-renewal, proliferation and migration rates, vasculogenic mimicry (VM), and in vivo tumorigenesis, in comparison with differentiated meningioma cells and stem-like cells isolated from normal meninges. These cell populations were challenged with CXCL12 and CXCL11 and receptor antagonists to define the chemokine role in stem cell-related functions.

resultsStem-like cells isolated from meningioma cultures display higher proliferation and migration rates, and VM, as compared to meningioma non-stem cells or cells isolated from normal meninges and were the only tumorigenic population in vivo. In meningioma cells, these stem-like functions were under the control of the CXCR4/CXCR7 chemokine axis.

conclusionsWe report a role for CXCL11 and CXCL12 in the control of malignant features in stem-like cells isolated from human meningioma, providing a possible basis for the aggressive clinical behavior observed in subsets of these tumors. CXCR4/CXCR7 antagonists might represent a useful approach for meningioma at high risk of recurrence and malignant progression.

Indexed as

Brain NeoplasmsMeningeal NeoplasmsMeningiomaReceptors, CXCRChemokine CXCL11Chemokine CXCL12HumansReceptors, CXCR4Signal TransductionChemokine CXCL11Chemokine CXCL12CXCL11 protein, humanCXCL12 protein, humanReceptors, CXCRReceptors, CXCR4CXCL11/CXCL12meningiomastem cellstumorigenesis

Identifiers

PMID37074930
PMCPMC10547527
OpenAlexW4366351895

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.